EGFR and pancreatic neoplasm: In a preclinical murine model of PDAC, addition of Bevacizumab and cetuximab (epidermal growth factor receptor (EGFR) inhibitory antibody) with gemcitabine/FOLOFRINOX significantly reduced pancreatic tumour weight compared to mice treated with chemotherapy alone [168].